Dushen Chetty is Development Head for the Breast and Genitourinary Disease Areas within Pfizer's Late-Stage Oncology organization, with accountability for late-stage strategy and execution across the breast and GU portfolio. His remit has recently expanded to include gynecologic oncology indications. Working with global program and line function leaders, he drives registrational studies, regulatory submissions, and portfolio strategy - while critically assessing internal and external opportunities to strengthen innovation and build a robust development pipeline. His teams advance programs spanning antibody-drug conjugates, targeted small molecules, immuno-oncology and bispecific antibodies, and novel combination regimens. 

Dushen joined Pfizer from Novartis, where he served as Head of Oncology and Hematology Development with overall accountability for the oncology and hematology development portfolio. He previously led prostate cancer development there, with a focus on PSMA-targeted radioligand therapies, directing teams across all Lu-PSMA and Ac-PSMA programs. His hematology work included a CAR-T program in multiple myeloma and the development of Kymriah across DLBCL and follicular lymphoma, and he has steered teams to regulatory approvals in pediatric glioma and a BRaf tumor-agnostic indication. 

Earlier, as Senior Director at Janssen Oncology, Dushen designed development strategies for hK2-targeting radio-conjugates in prostate cancer, a novel drug delivery device for bladder cancer, and an oncolytic virus program. During fifteen years at GlaxoSmithKline he evaluated new oncology opportunities in Worldwide Business Development, leading scientific licensing diligence and shaping BD strategy, and founded an R&D unit in Singapore during a two-year global assignment. 

Dushen holds a PhD from Rutgers University, where he was a Fulbright Scholar, and was a British Council Scholar at King's College London. As an Associate Professor at the University of Durban-Westville in South Africa, he led grant-funded research and founded a research program in drug delivery.